公开(公告)号：US11584737B2

公开(公告)日：2023-02-21

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji Ono ,  Masahiro Ito ,  Toshio Tanaka ,  Moriteru Asano ,  Takaharu Hirayama ,  Jun Fujimoto ,  Nobuki Sakauchi ,  Yasuhiro Hirata ,  Akinori Toita ,  Nao Morishita ,  Hironori Kokubo ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Douglas Robert Cary ,  Ryo Mizojiri ,  Nobuo Cho ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Yasuyoshi Arikawa

IPC: C07D401/14 ,  C07D403/14 ,  A61P35/00 ,  C07D213/84 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09957251B2

公开(公告)日：2018-05-01

申请号：US15304623

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Jun Fujimoto ,  Douglas Robert Cary ,  Masanori Okaniwa ,  Yasuhiro Hirata

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/08 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D409/04 ,  C07D409/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/107 ,  C07D498/08 ,  C07D213/64

CPC classification number: C07D401/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D213/64 ,  C07D401/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

公开(公告)号：US09682925B2

公开(公告)日：2017-06-20

申请号：US15005574

申请日：2016-01-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Shigeo Kajii ,  Douglas Robert Cary ,  Daisuke Tomita ,  Shinichi Imamura ,  Ken Tsuchida ,  Satoru Matsuda ,  Ryujiro Hara

IPC: A61K31/167 ,  A61K31/36 ,  A61K31/366 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/451 ,  A61K31/495 ,  A61K31/55 ,  C07C233/80 ,  A61K31/381 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/4468 ,  C07D309/14 ,  C07C271/22 ,  C07D317/58 ,  C07D223/16 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D333/20 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D405/04 ,  C07D239/36 ,  C07D409/04 ,  C07D471/04 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07C235/56 ,  C07D207/06 ,  C07C237/40 ,  C07D495/04 ,  C07D207/337 ,  C07D277/20 ,  C07D277/28 ,  C07D277/30 ,  C07D209/08 ,  C07D277/62 ,  C07D209/42 ,  C07D513/04 ,  C07D209/46 ,  C07D209/48 ,  C07D285/06 ,  C07D211/56 ,  C07D211/58 ,  C07D295/14 ,  C07D211/76 ,  C07D213/04 ,  C07D213/38 ,  C07D213/56 ,  C07D211/98 ,  C07D335/02 ,  C07C237/42 ,  C07C271/20 ,  C07D211/40 ,  C07D231/26 ,  C07D295/135 ,  C07D295/155

CPC classification number: C07C233/80 ,  A61K31/167 ,  A61K31/36 ,  A61K31/366 ,  A61K31/381 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/495 ,  A61K31/55 ,  C07C235/56 ,  C07C237/40 ,  C07C237/42 ,  C07C271/20 ,  C07C271/22 ,  C07C2601/02 ,  C07C2601/18 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/337 ,  C07D209/08 ,  C07D209/42 ,  C07D209/46 ,  C07D209/48 ,  C07D211/40 ,  C07D211/56 ,  C07D211/58 ,  C07D211/76 ,  C07D211/98 ,  C07D213/04 ,  C07D213/38 ,  C07D213/56 ,  C07D223/16 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D231/26 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D239/36 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07D277/20 ,  C07D277/28 ,  C07D277/30 ,  C07D277/62 ,  C07D285/06 ,  C07D295/135 ,  C07D295/14 ,  C07D295/155 ,  C07D309/14 ,  C07D317/58 ,  C07D333/20 ,  C07D335/02 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q1, Q2, Q3 and Q4 are each a hydrogen atom or a substituent; Q1 and Q2, and Q3 and Q4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y1, Y2 and Y3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y1, and Y1 and Y2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z1, Z2 and Z3 are each H or a substituent, or a salt thereof.

公开(公告)号：US10696651B2

公开(公告)日：2020-06-30

申请号：US16323863

申请日：2017-08-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jun Fujimoto ,  Xin Liu ,  Osamu Kurasawa ,  Terufumi Takagi ,  Douglas Robert Cary ,  Hiroshi Banno ,  Yasutomi Asano ,  Takuto Kojima

IPC: C07D401/12 ,  C07D403/12 ,  C07D401/14 ,  C07D213/75 ,  C07D405/12 ,  C07D239/42 ,  C07D241/12 ,  C07D471/04 ,  C07D498/04 ,  C07D213/65 ,  A61P35/00 ,  C07D241/20 ,  C07D213/73 ,  A61K31/53 ,  A61K31/505 ,  A61K31/4406 ,  A61K31/444 ,  A61K31/4965 ,  C07D213/68 ,  C07D213/42 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4375 ,  C07D239/20 ,  A61P43/00 ,  A61K31/5383 ,  A61K31/437 ,  A61K31/44 ,  C07D253/06 ,  C07D231/12 ,  C07D239/30 ,  C07D239/34 ,  C07D239/48 ,  C07D253/07 ,  C07D409/12 ,  C07D487/04

Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09745325B2

公开(公告)日：2017-08-29

申请号：US15304727

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masanori Okaniwa ,  Hiroshi Banno ,  Takaharu Hirayama ,  Douglas Robert Cary ,  Koji Ono ,  Naoki Iwamura

IPC: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

CPC classification number: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.